These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 3087015)

  • 41. Baseline fibrinolytic state and the risk of future venous thrombosis. A prospective study of endogenous tissue-type plasminogen activator and plasminogen activator inhibitor.
    Ridker PM; Vaughan DE; Stampfer MJ; Manson JE; Shen C; Newcomer LM; Goldhaber SZ; Hennekens CH
    Circulation; 1992 May; 85(5):1822-7. PubMed ID: 1572039
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Kinetic analysis of the interaction between plasminogen activator inhibitor-1 and tissue-type plasminogen activator.
    Masson C; Angles-Cano E
    Biochem J; 1988 Nov; 256(1):237-44. PubMed ID: 3146972
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Isolation of a new specific plasminogen activator inhibitor from pregnancy plasma.
    Lecander I; Astedt B
    Br J Haematol; 1986 Feb; 62(2):221-8. PubMed ID: 3484964
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Altered fibrinolysis in DVT: influence of site of sampling.
    Han P; Koay ES; Tsakok M; Aw TC; Wong LY; Pradhan M
    Thromb Haemost; 1988 Aug; 60(1):50-3. PubMed ID: 3142091
    [TBL] [Abstract][Full Text] [Related]  

  • 45. An inhibitor of plasminogen activation from human placenta. Purification and characterization.
    Wun TC; Reich E
    J Biol Chem; 1987 Mar; 262(8):3646-53. PubMed ID: 3102492
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Human endothelial cells produce a plasminogen activator inhibitor and a tissue-type plasminogen activator-inhibitor complex.
    Philips M; Juul AG; Thorsen S
    Biochim Biophys Acta; 1984 Nov; 802(1):99-110. PubMed ID: 6435688
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Interactions of tissue-type plasminogen activator with plasma inhibitors and their pharmacologic implications.
    Lucore CL; Sobel BE
    Circulation; 1988 Mar; 77(3):660-9. PubMed ID: 2449299
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Plasminogen activator inhibitor 1 (PAI) is bound to vitronectin in plasma.
    Wiman B; Almquist A; Sigurdardottir O; Lindahl T
    FEBS Lett; 1988 Dec; 242(1):125-8. PubMed ID: 2462509
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Acute endothelial tissue plasminogen activator release in pregnancy.
    Robb AO; Mills NL; Din JN; Cameron S; Ludlam CA; Newby DE; Denison FC
    J Thromb Haemost; 2009 Jan; 7(1):138-42. PubMed ID: 18983502
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Purification and characterization of natural and recombinant human plasminogen activator inhibitor-1 (PAI-1).
    Alessi MC; Declerck PJ; De Mol M; Nelles L; Collen D
    Eur J Biochem; 1988 Aug; 175(3):531-40. PubMed ID: 3261688
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Attenuation of thrombolysis by release of plasminogen activator inhibitor type-1 from platelets.
    Torr-Brown SR; Sobel BE
    Thromb Res; 1993 Dec; 72(5):413-21. PubMed ID: 8303684
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The majority of type 1 plasminogen activator inhibitor associated with cultured human endothelial cells is located under the cells and is accessible to solution-phase tissue-type plasminogen activator.
    Schleef RR; Podor TJ; Dunne E; Mimuro J; Loskutoff DJ
    J Cell Biol; 1990 Jan; 110(1):155-63. PubMed ID: 2104856
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A plasminogen activator inhibitor (PAI-2) circulates in two molecular forms during pregnancy.
    Booth NA; Reith A; Bennett B
    Thromb Haemost; 1988 Feb; 59(1):77-9. PubMed ID: 3129811
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Daytime fluctuations in blood of tissue-type plasminogen activator (t-PA) and its fast-acting inhibitor (PAI-1).
    Kluft C; Jie AF; Rijken DC; Verheijen JH
    Thromb Haemost; 1988 Apr; 59(2):329-32. PubMed ID: 3133814
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The mutation in fibrinogen Bicêtre II (gamma Asn308-->Lys) does not affect the binding of t-PA and plasminogen to fibrin.
    Grailhe P; Boyer-Neumann C; Haverkate F; Grimbergen J; Larrieu MJ; Anglés-Cano E
    Blood Coagul Fibrinolysis; 1993 Oct; 4(5):679-87. PubMed ID: 8292717
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay.
    Declerck PJ; Alessi MC; Verstreken M; Kruithof EK; Juhan-Vague I; Collen D
    Blood; 1988 Jan; 71(1):220-5. PubMed ID: 3257145
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Peptide-mediated inactivation of recombinant and platelet plasminogen activator inhibitor-1 in vitro.
    Eitzman DT; Fay WP; Lawrence DA; Francis-Chmura AM; Shore JD; Olson ST; Ginsburg D
    J Clin Invest; 1995 May; 95(5):2416-20. PubMed ID: 7738206
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Quantification of a specific inhibitor (PAI-1) of tissue-type plasminogen activator (t-PA) in the plasma].
    Masson C; Angles-Cano E
    Ann Biol Clin (Paris); 1989; 47(5):269-74. PubMed ID: 2500878
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Inhibition of one-chain and two-chain forms of human tissue-type plasminogen activator by the fast-acting inhibitor of plasminogen activator in vitro and in vivo.
    Colucci M; Paramo JA; Collen D
    J Lab Clin Med; 1986 Jul; 108(1):53-9. PubMed ID: 3086473
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Fibrinolysis during normal human pregnancy: complex inter-relationships between plasma levels of tissue plasminogen activator and inhibitors and the euglobulin clot lysis time.
    Wright JG; Cooper P; Astedt B; Lecander I; Wilde JT; Preston FE; Greaves M
    Br J Haematol; 1988 Jun; 69(2):253-8. PubMed ID: 3134043
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.